The estimated Net Worth of Richard John Wallace is at least $404 Thousand dollars as of 7 November 2023. Mr. Wallace owns over 10,000 units of Immunogen stock worth over $312,400 and over the last 17 years he sold IMGN stock worth over $0. In addition, he makes $91,766 as Independent Director at Immunogen.
Richard has made over 1 trades of the Immunogen stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of IMGN stock worth $147,000 on 7 November 2023.
The largest trade he's ever made was exercising 10,000 units of Immunogen stock on 7 November 2023 worth over $147,000. On average, Richard trades about 357 units every 0 days since 2007. As of 7 November 2023 he still owns at least 10,000 units of Immunogen stock.
You can see the complete history of Mr. Wallace stock trades at the bottom of the page.
Richard J. Wallace serves as Independent Director of the Company. Prior to that, he served in various executive capacities for GSK and its predecessor companies and their subsidiaries from 1992 to 2004. Mr. Wallace’s experience prior to joining GSK included eight years with Bristol-Myers Squibb Company, a pharmaceutical company, and seven years at Johnson & Johnson, a healthcare products and pharmaceutical company, in assignments spanning marketing, sales, manufacturing, and general management. Mr. Wallace is also a director of GNC Holdings, Inc.
As the Independent Director of Immunogen, the total compensation of Richard Wallace at Immunogen is $91,766. There are 9 executives at Immunogen getting paid more, with Mark Enyedy having the highest compensation of $3,917,560.
Richard Wallace is 68, he's been the Independent Director of Immunogen since 2007. There are no older and 15 younger executives at Immunogen.
Richard's mailing address filed with the SEC is 1578 SE BALLANTRAE COURT, , PORT SAINT LUCIE, FL, 34952.
Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding..., and Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
Immunogen executives and other stock owners filed with the SEC include: